Eli Lilly and Co. will pay at least $7 million to acquire rights to a diabetes compound developed by Toronto-based Transition Therapeutics Inc., the companies announced tonight.
Indianapolis-based Lilly will work with Transition to complete a Phase II trial of a compound called TT-223, which provided sustained improvement in blood sugar control during preclinical studies.
Under the terms of the agreement, Lilly could pay Transition up to $130 million if the company achieves certain development and sales goals. Transition would also receive royalties from any future commercial sales.
Please enable JavaScript to view this content.